Long-Term Benefit From Nivolumab Plus Cabozantinib in RCC Long-Term Benefit From Nivolumab Plus Cabozantinib in RCC

First-line nivolumab plus cabozantinib continues to show superiority to sunitinib in the treatment of patients with advanced advanced renal cell carcinoma (RCC).Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news